Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 855-862

  Jeune, Caroline Le ^a   Bertoli, Sarah ^b   Elhamri, Mohamed ^a   Vergez, Francois ^b   Borel, Cecile ^b   Huguet, Françoise ^b   Michallet, Mauricette ^a   Dumontet, Charles ^a   Recher, Christian ^b   Thomas, Xavier ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b CHU PURPAN   (France)

Author keywords

Absolute lymphocyte count; Acute myeloid leukemia; Chemotherapy; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ABSOLUTE LYMPHOCYTE COUNT; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHROMOSOME ANALYSIS; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; BLOOD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; PROGNOSIS; REMISSION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904339077     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.813504     Document Type: Article

References (46)

1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel, on behalf of the European LeukemiaNet.Blood 2010;115:453-474.
2. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368: 1894-1907. (Pubitemid 44794525)
3. GrimwadeD, Walker H, OliverF, et al. Theimportance ofdiagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-2333.
4. Blake-Mortimer JS, Sephton SE, Carlson RW, et al. Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer. Breast J 2004;10:195-199. (Pubitemid 38715734)
5. Fumagalli LA, Vinke J, Hoff W, et al. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003;26:394-402. (Pubitemid 37128551)
6. Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006; 32: 22-28. (Pubitemid 41803643)
7. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213. (Pubitemid 36077915)
8. Ceze N, Thibault G, Goujon G, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy.Cancer Chemother Pharmacol 2011; 68: 1305-1313.
9. VanGlabbekeM, VanOosteromAT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2, 185 patients treated with anthracycline- containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-157. (Pubitemid 29022388)
10. Hasenclever D, DiehlV. Aprognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
11. Oki Y, Yamamoto K, Kato H, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 2008;81:448-453.
12. Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006; 134: 596-601. (Pubitemid 44253601)
13. Ege H, Gertz MA, Markovic SN, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study.Br J Haematol 2008; 141: 792-798. (Pubitemid 351724861)
14. Jacobs NL, Holtan SG, Porrata LF, et al. Host immunity affects survival in myelodysplastic syndromes:Independent prognostic value of the absolute lymphocyte count. Am J Hematol 2010;85:160-163.
15. Porrata LF, Rsitow K, Inwards DJ, et al. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia 2010; 24: 1343-1349.
16. Behl D, Porrata LF, Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006; 20: 29-34.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-458.
18. Chevallier P, Fornecker L, Lioure B, et al. Tandem versus single autologous peripheral blood stem cell transplantation as post- remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial.Leukemia 2010; 24: 1380-1385.
19. Lioure B, Bene MC, Pigneux A, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.Blood 2012; 119: 2943-2948.
20. Pigneux A, Harousseau JL, Witz F, et al. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. J Clin Oncol 2010;28:3028-3034.
21. Archimbaud E, Thomas X, Michallet M, et al. Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 1994; 12: 262-267. (Pubitemid 24056398)
22. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010; 28: 808-814.
23. Thomas X, Chelghoum Y, Cannas G, et al. Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making? Clin Lymphoma Myeloma Leuk 2011;11:342-349.
24. Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 2011; 118: 1754-1762.
25. An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature. Birth Defects Orig Artic Ser 1985; 21: 1-117.
26. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649. (Pubitemid 46594039)
27. Rogers SY, Bradbury D, Kozlowski R, et al. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol 1994; 22: 593-598. (Pubitemid 24300494)
28. Oster W, Cicco NA, Klein H, et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control.J Clin Invest 1989; 84: 451-457. (Pubitemid 19196975)
29. Thomas X, Hirschauer C, Troncy J, et al. Serum interleukin-6 levels in adult acute myelogenous leukemia:relationship with disease characteristics and outcome. Leuk Lymphoma 1997; 24: 291-300. (Pubitemid 27101600)
30. Blay JY, Farcet JP, Lavaud A, et al. Serum concentrations of cyto- kines in patients with Hodgkin's disease. Eur J Cancer 1994;30A:321-324. (Pubitemid 24152471)
31. Casasnovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:1732-1740. (Pubitemid 46797954)
32. Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003;88:181-186. (Pubitemid 36255833)
33. Ray-Coquard I, Cesne AL, Rubio MT, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol 1999;17:2840-2840.
34. Blay JY, Cesne AL, Mermet C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy.Blood 1998; 92: 405-410. (Pubitemid 28323701)
35. Ray-Coquard I, Ghesquiere H, Bachelot T, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001; 85: 816-822. (Pubitemid 33010546)
36. Borg C, Ray-Coquard I, Philip I, et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004;101:2675- 2680. (Pubitemid 39532301)
37. Lissoni P, Brivio F, Fumagalli L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004;19:135- 140. (Pubitemid 39106939)
38. Nelson DS. Immunity to infection, allograft immunity and tumour immunity: parallels and contrasts. Transplant Rev 1974;19:226-254.
39. Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8: 2553-2562. (Pubitemid 34856339)
40. Dworacki G, Meidenbauer N, Kuss I, et al. Decreased zeta chain expression and apoptosis in CD3 + peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001;7(Suppl. 3):947s-957s. (Pubitemid 33600950)
41. Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002; 117 :821-827. (Pubitemid 34639242)
42. Fauriat C, Just-Landi S, Mallet F, et al. Deficient expression ofNCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.Blood 2007; 109: 323-330. (Pubitemid 46053073)
43. Dauguet N, Recher C, Demur C, et al. Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission. Am J Hematol 2011;86:209-213.
44. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-2228. (Pubitemid 24296382)
45. Rey J, Veuillen C, Vey N, et al. Natural killer and gammadelta T cells in haematological malignancies:enhancing the immune effectors. Trends Mol Med 2009; 15: 275-284.
46. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009;69:5383-5391.